Mesothelioma Molecular and Genetic Testing

Molecular & Genetic Testing
Genomic Profiling for Mesothelioma
Category	Diagnostic / Medical
Most Common Alteration	BAP1 Loss (60%)
BAP1 IHC Specificity	86%
CDKN2A FISH Specificity	100%
NF2 Alteration Rate	30–40%
Germline BAP1 Rate	9–12% of PM patients
Mesothelioma TMB	Low (~1.8 mut/Mb)
Key NGS Platform	FoundationOne CDx (324 genes)
Free Case Review →

Molecular and genetic testing has fundamentally transformed the diagnosis and management of malignant mesothelioma, moving the field beyond traditional histologic classification toward precision oncology approaches that match patients with targeted therapies and clinical trials. The three most clinically significant molecular alterations in mesothelioma are BAP1 loss (found in approximately 60% of pleural mesotheliomas), CDKN2A homozygous deletion (45–74% of pleural cases), and NF2 inactivation (30–40%), each providing both diagnostic and prognostic information that directly impacts patient care.

BAP1 immunohistochemistry and CDKN2A fluorescence in situ hybridization represent the two most important ancillary tests for distinguishing malignant mesothelioma from reactive mesothelial proliferations, a diagnostic challenge that has historically delayed treatment. BAP1 IHC achieves 53% sensitivity with 86% specificity, while CDKN2A FISH achieves 41–61% sensitivity with 100% specificity — meaning a positive CDKN2A FISH result definitively confirms malignancy. When combined, these tests significantly improve diagnostic accuracy beyond either test alone.

Next-generation sequencing panels such as FoundationOne CDx (324 genes) and MSK-IMPACT (341 genes) enable comprehensive genomic profiling that identifies rare actionable mutations in 1–2% of cases, including ALK rearrangements responsive to targeted therapy. For the 9–12% of mesothelioma patients carrying germline BAP1 mutations, genetic testing triggers cascade screening of family members and lifelong cancer surveillance, as these mutations confer a 30% lifetime risk of mesothelioma along with elevated risks of uveal melanoma, renal cell carcinoma, and other cancers.

Mesothelioma molecular and genetic testing at a glance:

• BAP1 loss prevalence — detected in approximately 60% of pleural mesotheliomas and up to 80% of epithelioid subtype tumors
• CDKN2A FISH specificity — achieves 100% specificity for distinguishing malignant mesothelioma from benign mesothelial tissue
• NF2/merlin inactivation — occurs in 30–40% of mesotheliomas with biallelic loss in 40% of TCGA-analyzed samples
• CDKN2A deletion rate — homozygous deletion found in 45–74% of pleural and 25–35% of peritoneal mesotheliomas
• Germline BAP1 mutations — present in 9–12% of pleural mesothelioma patients, conferring 7-fold improved 10-year survival (26% vs. sporadic)
• NGS platform coverage — FoundationOne CDx analyzes 324 genes while MSK-IMPACT covers 341 cancer-associated genes
• Tumor mutational burden — mesothelioma shows consistently low TMB at approximately 1.8 mutations per megabase across all subtypes
• Liquid biopsy accuracy — cell-free DNA methylation profiling achieved 91% accuracy distinguishing mesothelioma from asbestos-exposed controls
• Rare actionable mutations — ALK fusions, KRAS G12C, and BRCA1/2 variants found in 1–2% of patients eligible for targeted therapy
• PD-L1 expression — present at the ≥1% threshold in 20–50% of mesotheliomas but not validated as a reliable immunotherapy predictor

Key Facts: Mesothelioma Molecular and Genetic Testing

BAP1 protein loss is the single most important biomarker for distinguishing malignant mesothelioma from reactive mesothelial proliferations, detected by standard immunohistochemistry CDKN2A FISH achieves 100% specificity for mesothelioma diagnosis — a positive result is never found in benign mesothelial tissue Approximately 9–12% of pleural mesothelioma patients carry germline BAP1 mutations, requiring genetic counseling and family cascade testing Patients with germline BAP1 mutations show 7-fold improved long-term survival, with 26% surviving 10 or more years compared to sporadic cases NF2/merlin inactivation occurs in 30–40% of mesotheliomas and activates the Hippo signaling pathway, now targeted by novel TEAD inhibitors in clinical trials Mesothelioma has consistently low tumor mutational burden (~1.8 mut/Mb), limiting the utility of TMB as a predictive biomarker for immunotherapy PD-L1 expression (≥1%) is found in 20–50% of mesotheliomas but does not reliably predict immunotherapy response per CheckMate 743 and KEYNOTE-483 data Next-generation sequencing panels identify rare actionable mutations (ALK fusions, KRAS G12C) in 1–2% of patients eligible for targeted therapy DNA methylation profiling of plasma cell-free DNA achieved 91% accuracy in distinguishing mesothelioma from asbestos-exposed controls in a 2025 ASCO study The MiST trial platform uses molecular stratification to match patients with biomarker-guided therapies including rucaparib for BAP1 deficiency and abemaciclib for CDKN2A loss Combined BAP1 IHC plus CDKN2A FISH testing is now standard practice in mesothelioma diagnostic workups, particularly for challenging small biopsies and cytology specimens

What Is BAP1 and Why Is It the Most Important Mesothelioma Gene?

BAP1 (BRCA1-Associated Protein 1) is a tumor suppressor gene located on chromosome 3p21.1 that encodes a 729-amino-acid nuclear deubiquitinase enzyme. This protein forms multiprotein complexes that regulate genomic stability, DNA repair, chromatin remodeling, cell cycle control, and programmed cell death. BAP1 is normally expressed in all mesothelial cells, and its loss represents the most common molecular alteration in pleural mesothelioma — an early event in the disease's pathogenesis that has been detected even in mesothelioma in situ, the earliest recognizable stage of the cancer.

BAP1 inactivation occurs through two biologically distinct pathways with different clinical implications. Somatic mutations, which account for 70–80% of BAP1 alterations, arise from acquired genetic changes including single nucleotide variants, chromosomal rearrangements, gene fusions, and splice-site alterations. These somatic changes are found in approximately 60% of all pleural mesotheliomas and up to 80% of the epithelioid histological subtype. A retrospective study of 217 mesothelioma patients confirmed that somatic BAP1 mutations were the single most frequent genomic alteration, occurring in 45.6% of cases analyzed by next-generation sequencing.

Germline BAP1 mutations, found in 9–12% of pleural mesothelioma patients, represent inherited cancer susceptibility variants that follow an autosomal dominant pattern with incomplete penetrance. Approximately 30% of individuals carrying these mutations will develop mesothelioma during their lifetime. These patients present at notably younger ages (mean 54–56 years versus 72 years for sporadic cases) and show a near-equal sex distribution, in contrast to the male predominance seen in asbestos-related sporadic mesothelioma. The identification of germline BAP1 mutations has profound implications for family members, who have a 50% probability of inheriting the variant and require genetic counseling and cancer surveillance.

BAP1 Immunohistochemistry in Diagnostic Pathology

BAP1 immunohistochemistry has become a standard diagnostic tool in mesothelioma pathology. The test detects loss of nuclear BAP1 protein staining in mesothelial cells, which is highly specific for malignancy. In a paired diagnostic study comparing BAP1 IHC with CDKN2A FISH, BAP1 immunohistochemistry yielded approximately 53% sensitivity and 86% specificity for malignant mesothelioma in effusion specimens. The test's primary clinical value lies in its ability to distinguish malignant mesothelioma from reactive mesothelial proliferations — a differential diagnosis that pathologists frequently encounter when evaluating pleural or peritoneal biopsies and fluid cytology specimens.

The combination of BAP1 IHC with CDKN2A FISH provides complementary diagnostic information: BAP1 offers higher sensitivity while CDKN2A FISH achieves perfect specificity. Together, these two tests substantially improve diagnostic accuracy beyond either test alone and have become the recommended ancillary testing panel for challenging mesothelioma diagnostic cases.

BAP1 Tumor Predisposition Syndrome

BAP1 Tumor Predisposition Syndrome (BAP1-TPDS) is a hereditary cancer syndrome that predisposes carriers to multiple malignancies. The cancer spectrum associated with germline BAP1 mutations includes mesothelioma (30% of carriers), uveal melanoma (18%), cutaneous melanoma (14%), clear cell renal cell carcinoma (7%), and basal cell carcinoma (6%). Affected families characteristically show multi-generational clustering of these cancers, often with multiple family members developing different BAP1-associated malignancies.

Carriers and their first-degree relatives require comprehensive genetic counseling and ongoing surveillance that includes dermatologic examination for skin cancers, ophthalmologic screening for uveal melanoma, abdominal imaging for renal cell carcinoma, and chest MRI for early detection of mesothelioma. The recognition of BAP1-TPDS has fundamentally changed the clinical approach to younger mesothelioma patients and those with suggestive family histories, as identifying the syndrome triggers cascade genetic testing that can protect at-risk family members through early surveillance.

Prognostic Significance of BAP1 Alterations

The prognostic significance of BAP1 in mesothelioma is context-dependent and differs between germline and somatic alterations. Germline BAP1 mutations are consistently associated with improved prognosis, with a median survival of approximately 5–7 years and 26% of patients surviving 10 or more years — representing a 7-fold improvement compared with sporadic mesothelioma in the SEER database. Tumors in germline carriers tend to be epithelioid with favorable histologic features including bland nuclei, rare mitoses, and absence of necrosis.

In contrast, the prognostic impact of somatic BAP1 loss remains unclear. Some studies found that somatic BAP1 loss was associated with improved median survival (16 versus 6 months in a 229-patient cohort), while others demonstrated worse outcomes or no significant difference. A meta-analysis of 698 patients found no statistically significant survival difference based on somatic BAP1 status, and currently, somatic BAP1 is not validated as an independent prognostic factor in multivariate analyses.

How Does CDKN2A Testing Confirm a Mesothelioma Diagnosis?

The CDKN2A gene, located on chromosome 9p21, encodes two critical tumor suppressor proteins — p16INK4A and p14ARF — that regulate the cell cycle through CDK4/6 inhibition and the MDM2/p53 pathway, respectively. Homozygous deletion of CDKN2A is one of the most frequent genetic alterations in pleural mesothelioma, occurring in 45–74% of cases. In peritoneal mesothelioma, the deletion rate is lower at approximately 25–35%, reflecting the different molecular biology of these two disease entities.

Fluorescence in situ hybridization (FISH) using dual-color probes for CDKN2A and the chromosome 9 centromere (CEP-9) is the standard method for detecting homozygous deletion. The test defines homozygous deletion as loss of both CDKN2A signals in the presence of at least one CEP-9 signal in more than 15% of examined nuclei. This methodology can be applied to tissue sections, cell blocks, and cytology preparations, making it versatile across different specimen types.

Diagnostic Specificity and Sensitivity

The primary diagnostic value of CDKN2A FISH lies in its unmatched specificity for distinguishing malignant mesothelioma from reactive mesothelial proliferations — a diagnostic challenge that historically delayed appropriate treatment. CDKN2A FISH for homozygous deletion achieves 100% specificity, meaning the test is never positive in reactive mesothelial tissue. When the test detects homozygous deletion, the diagnosis of malignancy is definitively confirmed. The sensitivity of the test ranges from 41% to 61% across published studies, limited by the fact that not all mesotheliomas harbor this particular deletion.

A recently validated chromogenic in situ hybridization (CISH) probe for CDKN2A provides equivalent diagnostic information to standard FISH but can be scored using an ordinary light microscope rather than requiring specialized fluorescence equipment. This technical advance has the potential to significantly broaden clinical accessibility, particularly at community pathology laboratories that may lack fluorescence microscopy capabilities.

Prognostic Implications of CDKN2A Deletion

Beyond its diagnostic role, CDKN2A deletion carries important prognostic significance. Homozygous deletion is a strong predictor of poor survival in both pleural and peritoneal mesothelioma. An ASCO 2023 study demonstrated that CDKN2A-mutated mesothelioma was associated with significantly worse overall survival compared to CDKN2A-intact tumors, and the deletion has been incorporated into molecular prognostic models that aim to refine treatment decision-making.

What Role Does NF2/Merlin Inactivation Play in Mesothelioma?

NF2 encodes the protein merlin (Moesin-Ezrin-Radixin-Like Protein), a membrane-scaffolding tumor suppressor that belongs to the ERM protein family. NF2 inactivation occurs in 30–40% of mesotheliomas through somatic mutations, deletions, or allelic losses. Data from The Cancer Genome Atlas (TCGA) showed monoallelic NF2 deletions in 34% and biallelic inactivation in an additional 40% of analyzed pleural mesothelioma samples, making NF2 the third most commonly altered gene after BAP1 and CDKN2A.

Evolutionary genomic analysis suggests that NF2 loss is a relatively late event in mesothelioma development compared to BAP1, which is characteristically early. This temporal relationship has implications for disease progression, as NF2 loss may represent a clonal evolution step that confers a more aggressive phenotype. The timing of NF2 inactivation in mesothelioma pathogenesis also provides insights into potential therapeutic windows for early intervention.

The Hippo Signaling Pathway and Therapeutic Targets

Merlin is a critical upstream regulator of the highly conserved Hippo tumor-suppressive signaling pathway, one of the most important cancer-relevant pathways disrupted in mesothelioma. When merlin is functional, it activates MST1/2 kinases, which phosphorylate and activate LATS1/2 kinases. Active LATS1/2 then phosphorylates the transcriptional co-activators YAP and TAZ, sequestering them in the cytoplasm and targeting them for degradation. When merlin is lost through NF2 inactivation, YAP and TAZ translocate to the nucleus, bind TEAD transcription factors, and drive expression of genes promoting cell proliferation, survival, and resistance to apoptosis.

Beyond the Hippo pathway, merlin also regulates the mTOR, FAK, and PI3K/Akt signaling pathways, creating multiple potential therapeutic intervention points. Novel TEAD inhibitors, including IAG 933 and VT3989, have demonstrated preclinical activity in NF2-deficient mesothelioma cell lines and have entered early-phase clinical trials. These Hippo pathway-targeted agents represent a promising new therapeutic class specifically designed for the molecular profile frequently seen in mesothelioma.

What Information Does Next-Generation Sequencing Provide?

Next-generation sequencing (NGS) enables comprehensive genomic profiling of mesothelioma tumors, simultaneously analyzing hundreds of cancer-associated genes to identify mutations, copy number alterations, gene fusions, and genomic signatures such as tumor mutational burden and microsatellite instability. Several validated NGS platforms have been applied to mesothelioma molecular profiling, each with distinct gene coverage and analytical capabilities.

FoundationOne CDx, one of the most widely used platforms, covers 324 genes and detects substitutions, insertions/deletions, copy number alterations, select gene fusions, TMB, and MSI status. MSK-IMPACT analyzes all exons and selected introns of 341 cancer genes. The UCSF 500 Panel covers 510 genes and has been particularly utilized in peritoneal mesothelioma studies. These platforms provide the comprehensive molecular data needed to identify patients for biomarker-stratified clinical trials and rare targeted therapy opportunities.

Commonly Altered Genes in Mesothelioma

Across multiple whole-exome and targeted NGS studies, the most frequently altered genes in mesothelioma consistently include BAP1 (23–60% of cases), CDKN2A/2B (25–49%), NF2 (23–40%), TP53 (8–17%), SETD2 (8–22%), and LATS2 (approximately 11%). This molecular landscape is notable for being dominated by tumor suppressor gene losses rather than activating oncogene mutations, distinguishing mesothelioma from cancers like non-small cell lung cancer where driver oncogenes frequently offer direct therapeutic targets.

Rare Actionable Mutations

While the predominance of tumor suppressor losses limits directly targetable alterations in most mesothelioma cases, rare but clinically significant actionable mutations have been identified in approximately 1–2% of patients. ALK rearrangements, found particularly in peritoneal mesothelioma, can be treated with approved ALK inhibitors including crizotinib, ceritinib, and alectinib. KRAS mutations, occurring in approximately 1% of cases, may be targetable with KRAS G12C inhibitors. BRCA1/2 and homologous recombination repair gene mutations, present in approximately 7% of patients as germline variants, suggest potential sensitivity to PARP inhibitors. Additional rare alterations in PDGFRA/B, EGFR, ERBB2, FGFR3, and NTRK fusion genes each occur in less than 1% of cases but may qualify patients for approved targeted therapies.

How Does Epigenetic Testing and Methylation Profiling Aid Diagnosis?

Epigenetic alterations, particularly changes in DNA methylation patterns, play a significant and increasingly recognized role in mesothelioma biology. Unlike genetic mutations that alter the DNA sequence itself, epigenetic modifications change how genes are expressed without modifying the underlying genetic code. DNA methylation profiling has emerged as a powerful diagnostic and prognostic tool, capable of distinguishing malignant mesothelioma from normal mesothelium and predicting patient outcomes with remarkable accuracy.

Genome-wide methylation profiling studies have demonstrated that mesothelioma tumors exhibit distinct methylation signatures compared to normal pleural tissue, achieving misclassification error rates as low as 3.4% in random forests classification models. A landmark 2025 study presented at ASCO demonstrated that cell-free methylated DNA immunoprecipitation sequencing (cfMeDIP-seq) of plasma cell-free DNA achieved 91% accuracy in distinguishing pleural mesothelioma from asbestos-exposed non-cancer controls, with 88% precision — representing a major advance in non-invasive liquid biopsy diagnostics.

Methylation-based classification has identified two distinct molecular classes of pleural mesothelioma: a CIMP (CpG island methylator phenotype) hyper-methylated class and a LOW hypo-methylated class. These classes exist independently of histological subtype and carry implications for immune phenotype and immunotherapy response, potentially enabling more refined treatment selection in the future.

Emerging Applications of Epigenetic Testing

Several innovative applications of epigenetic testing are under active clinical development. CDKN2A promoter methylation can cause p16 protein loss without homozygous gene deletion, explaining diagnostic discrepancies where immunohistochemistry shows protein loss but FISH fails to detect a genomic deletion. Blood-based DNA methylation analysis at specific CpG sites, including FKBP5 and MLLT1, has shown potential for improving mesothelioma risk assessment in asbestos-exposed worker populations. Treatment with DNA hypomethylating agents such as guadecitabine can shift mesothelioma cells toward a more immune-favorable phenotype, providing scientific rationale for combination regimens with immune checkpoint inhibitors. Circulating microRNAs represent the most extensively studied class of epigenetic biomarkers in mesothelioma and demonstrate promise for non-invasive early detection.

What Does PD-L1 Expression Testing Reveal About Immunotherapy Response?

PD-L1 (Programmed Death-Ligand 1) protein expression has been extensively studied as a potential predictive biomarker for immunotherapy in mesothelioma. PD-L1 is expressed in approximately 20–50% of mesotheliomas at the commonly used ≥1% threshold, with higher expression rates observed in the sarcomatoid subtype compared to epithelioid tumors. Two main scoring approaches are used in clinical practice: Tumor Proportion Score (TPS), which measures the percentage of tumor cells with PD-L1 membrane staining, and Combined Positive Score (CPS), which incorporates staining on both tumor cells and tumor-infiltrating immune cells.

No standardized PD-L1 cutoff has been established specifically for mesothelioma, and different immunohistochemistry antibody clones (22C3, 28-8, SP263) may yield varying results on the same tissue sample. This lack of standardization complicates clinical interpretation and contributes to the ongoing debate about PD-L1's utility as a treatment selection biomarker in this disease.

Evidence from Pivotal Immunotherapy Trials

The pivotal CheckMate 743 trial, which randomized 605 patients to nivolumab plus ipilimumab versus platinum-pemetrexed chemotherapy, provided the most extensive PD-L1 analysis in mesothelioma. In patients with PD-L1 expression ≥1%, median overall survival was 18.0 months with immunotherapy versus 13.3 months with chemotherapy (hazard ratio 0.69). However, in patients with PD-L1 expression below 1%, outcomes were similar between arms at 17.3 versus 16.5 months (hazard ratio 0.94). Critically, no statistically significant interaction between PD-L1 status and treatment effect was observed, and the apparent difference was driven more by poorer chemotherapy performance in PD-L1-positive patients than by differential immunotherapy benefit.

At three-year follow-up, clinical benefit with nivolumab plus ipilimumab was observed across patient subgroups regardless of PD-L1 expression level. An exploratory four-gene inflammatory signature incorporating CD8A, PD-L1, STAT-1, and LAG-3 showed association with overall survival for the immunotherapy arm but has not yet been validated as a predictive biomarker.

KEYNOTE-483 exploratory analyses similarly demonstrated that chemoimmunotherapy efficacy was largely independent of PD-L1 status, with median overall survival of 20.0 versus 15.6 months in the PD-L1-positive subgroup and 15.6 versus 13.1 months in the PD-L1-negative subgroup. Based on this evidence, current clinical guidelines do not recommend using PD-L1 expression to exclude patients from immunotherapy treatment.

Why Is Tumor Mutational Burden Low in Mesothelioma?

Tumor mutational burden (TMB) quantifies the total number of somatic coding mutations per megabase of sequenced tumor genome. TMB has emerged as a predictive biomarker for immunotherapy response across multiple cancer types, including the tumor-agnostic FDA approval of pembrolizumab for tumors with TMB ≥10 mutations per megabase. However, mesothelioma is characterized by consistently low TMB across all studies and histological subtypes, substantially limiting this biomarker's clinical utility in this disease.

The Bueno et al. whole-exome sequencing study of 216 pleural mesothelioma patients confirmed a low overall protein-coding mutation rate. Peritoneal mesothelioma shows a median TMB of 1.8 mutations per megabase, and a comprehensive analysis of 1,294 mesothelioma samples found TMB was consistently low regardless of BAP1 alteration status. The low mutation rate in mesothelioma reflects its predominant mechanism of carcinogenesis through tumor suppressor gene loss and chromosomal deletions rather than the accumulation of point mutations seen in carcinogen-exposed cancers like smoking-related lung cancer.

TMB and Immunotherapy in Mesothelioma

Despite the validated role of TMB in immunotherapy patient selection for other cancer types, TMB has not proven useful for guiding mesothelioma immunotherapy decisions. In the CheckMate 743 biomarker analysis, TMB did not correlate with overall survival in either the immunotherapy or chemotherapy arms. The KEYNOTE-158 mesothelioma cohort confirmed low median TMB (approximately 1.26 mutations per megabase) with no predictive value for pembrolizumab response. Unlike TMB, features of the tumor immune microenvironment — including tumor-infiltrating lymphocyte density, macrophage infiltration patterns, and inflammatory gene signatures — appear to be more relevant biomarkers for predicting immunotherapy response in mesothelioma.

When Should Patients Undergo Molecular Testing and What Do Guidelines Recommend?

Molecular testing influences clinical management of mesothelioma at multiple critical decision points, from initial diagnosis through treatment selection and ongoing monitoring. Understanding when and how molecular testing changes treatment decisions is essential for patients, families, and healthcare teams navigating this complex disease.

Diagnostic Confirmation

BAP1 immunohistochemistry and CDKN2A FISH or CISH are essential ancillary tests for confirming the diagnosis of malignant mesothelioma, particularly in challenging specimens. Small biopsies, cytology preparations, and cases where the pathologic differential diagnosis includes reactive mesothelial proliferation all benefit from molecular confirmation. The combined use of these tests has significantly reduced diagnostic delays and misdiagnoses that historically hampered timely treatment initiation.

Germline Screening and Family Implications

Detection of somatic BAP1 loss in a mesothelioma specimen should prompt consideration of germline testing, particularly when the variant allele frequency exceeds 10% (suggesting a germline rather than purely somatic event). Confirmed germline BAP1 mutations trigger cascade testing of family members, comprehensive genetic counseling, and implementation of lifelong cancer surveillance protocols. Clinical features suggesting germline BAP1 involvement include younger age at diagnosis, family history of mesothelioma or other BAP1-associated cancers (uveal melanoma, renal cell carcinoma, cutaneous melanoma), and epithelioid histology with favorable pathologic features.

Treatment Selection and Clinical Trial Matching

While PD-L1 and TMB do not reliably guide first-line therapy selection, histological subtype informed by molecular features influences the choice between dual immunotherapy (nivolumab plus ipilimumab, favored for non-epithelioid histology based on CheckMate 743) and chemoimmunotherapy (pembrolizumab plus platinum-pemetrexed, favored for epithelioid histology based on KEYNOTE-483). NGS results play an increasingly important role in identifying patients for molecularly stratified clinical trials, such as the MiST platform trial that matches patients with biomarker-guided therapies including rucaparib for BAP1/BRCA2 deficiency and abemaciclib for CDKN2A loss.

NCCN Guideline Recommendations

The NCCN Clinical Practice Guidelines for Mesothelioma include several molecular testing-related recommendations. Both nivolumab plus ipilimumab and pembrolizumab plus platinum-pemetrexed are approved first-line options for unresectable pleural mesothelioma, with PD-L1 testing explicitly not required for treatment selection. BAP1 immunohistochemistry is routinely recommended in the mesothelioma diagnostic workup, and CDKN2A FISH is specifically indicated for challenging diagnostic scenarios. While no specific NCCN mandate exists for comprehensive NGS in mesothelioma (unlike non-small cell lung cancer), molecular profiling is increasingly recognized as valuable for clinical trial identification and detection of rare actionable mutations. Germline BAP1 testing is recommended for patients with clinical features suggestive of BAP1 tumor predisposition syndrome.

How Does Molecular Testing Apply to Mesothelioma Legal Claims?

Molecular and genetic testing results have become increasingly relevant to mesothelioma legal claims and compensation proceedings. The identification of specific molecular alterations can provide important evidence in establishing the causation link between asbestos exposure and mesothelioma development, particularly in cases where exposure history is complex or disputed. Genetic testing confirming germline BAP1 mutations does not negate asbestos causation claims, as research has established that asbestos exposure remains a necessary co-factor in mesothelioma development even in genetically predisposed individuals.

The documentation of molecular test results also supports claims for comprehensive medical treatment coverage, including eligibility for targeted therapies and enrollment in clinical trials that may not be available through standard care. Trust fund claims and litigation settlements often account for the full scope of diagnostic testing and treatment costs, and detailed molecular profiles can strengthen the medical evidence supporting these claims. Patients diagnosed through advanced molecular techniques may have documentation that more clearly establishes their diagnosis, supporting both individual claims and potential family exposure claims when germline mutations reveal hereditary cancer risk.

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.